Oxford Biomedica plc (LON:OXB) Insider Michael Hayden Buys 10,000 Shares of Stock

Oxford Biomedica plc (LON:OXBGet Free Report) insider Michael Hayden acquired 10,000 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was purchased at an average cost of GBX 193 ($2.37) per share, for a total transaction of £19,300 ($23,701.34).

Oxford Biomedica Stock Up 8.7 %

Shares of Oxford Biomedica stock opened at GBX 210 ($2.58) on Wednesday. The stock’s fifty day moving average is GBX 260.64 and its 200-day moving average is GBX 360.34. The firm has a market capitalization of £203.24 million, a PE ratio of -328.13 and a beta of 1.02. The company has a quick ratio of 1.67, a current ratio of 3.32 and a debt-to-equity ratio of 57.10. Oxford Biomedica plc has a 12-month low of GBX 190.20 ($2.34) and a 12-month high of GBX 575 ($7.06).

Analysts Set New Price Targets

Separately, Liberum Capital dropped their price objective on Oxford Biomedica from GBX 350 ($4.30) to GBX 310 ($3.81) and set a “hold” rating on the stock in a research note on Tuesday, September 26th.

View Our Latest Report on OXB

Oxford Biomedica Company Profile

(Get Free Report)

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.

Recommended Stories

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.